Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Novel drugs in the R/R MM: IMiDs

Enrique Ocio • 12 May 2020
COMy Virtual 2020
Multiple Myeloma Bortezomib Carfilzomib CC-92480 Daratumumab Iberdomide Lenalidomide Pomalidomide Thalidomide

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses novel drugs in the relapsed/refractory (R/R) multiple myeloma (MM). Specifically, immunomodulatory drugs (IMiDS) such as lenalidomide, pomalidomide and iberdomide. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals